Revive Therapeutics (RVV.C), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare diseases, announced today that it has entered into…
Revive Therapeutics
Revive Therapeutics (RVV.C) signed a research agreement with the University of California, San Francisco (UCSF) to explore Bucillamine as a potential treatment for severe cases of COVID-19 today, according…
“Psilocybin offers a potential solution to manage moderate to severe cases of TBI,” stated RVV, “Psilocybin has the potential with its neuroreparative effect to improve loss of cognitive function…
Pfizer & Moderna – two very different companies President Biden’s goal to vaccinate between 70% and 85% of the U.S. population, which is roughly 230 million – 280 million…
Revive Therapeutic (RVV.C) announced they have received positive results from a pre-clinical study evaluating the efficacy of psilocybin for the treatment of mild traumatic brain injury (TBI) in a rodent model of…
+135k shares in a downturn, my man The psychedelics sector is down bad this week. Just look at the psychedelics ETF PSYK.NE. It’s not an alarm or…
Revive Therapeutics (RVV.C) provided an update on their Phase 3 clinical trial for bucillamine for COVID-19 today. Primarily, the update’s about funding and more specifically their recent $23 million…
Humming in Q1 I’ve had a rough year, but Revive (RVV.C) sure hasn’t. With a portfolio based around psychedelics, cannabis, and diseases – this company has made 3…
Revive Therapeutics (RVV.C) advanced the December 21 deal with Newscope Capital (PHRM.C) past a binding LOI and into a purchase agreement to acquire psilocybin intellectual property from Newscope’s subsidiary,…
Mother nature Am I a true hippy, or do I have an impulsive personality that morphs and changes due to a lack of identity? My therapist thinks…